Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Y90-RE in mCRC with liver metastases
NCT04108481Phase 1Terminated
- Sponsor
- University of Iowa
- Start
- Oct 2020
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in colorectal cancer (metastatic) (mCRC) and liver metastasis, sponsored by University of Iowa. Primary endpoint: Maximum Tolerated Dose at 8 weeks. Started Oct 2020; status: terminated.
02
Drugs
durvalumab
03
Conditions
colorectal cancer (metastatic) (mCRC)liver metastasis
Beyond the preview
Go deeper on NCT04108481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108481.